Ligand Pharmaceuticals (LGND) Other Non-Current Assets (2010 - 2026)

Ligand Pharmaceuticals has reported Other Non-Current Assets for 17 years, with the latest figure at $13.0 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 64.56% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 64.56% YoY) and the FY2025 annual result came in at $12.6 million, down 60.35% from the prior year.
• Other Non-Current Assets climbed to $13.0 million in Q1 2026 per LGND's latest filing, from $12.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $31.7 million in Q4 2024 and troughed at $1.7 million in Q4 2022.
• A 5-year average of $9.0 million and a median of $7.9 million in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 396.4% in 2024, then plunged 67.03% in 2025.
• Over 5 years, Other Non-Current Assets stood at $1.7 million in 2022, then jumped by 268.2% to $6.4 million in 2023, then jumped by 396.4% to $31.7 million in 2024, then slumped by 60.35% to $12.6 million in 2025, then increased by 3.22% to $13.0 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $13.0 million, $12.6 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.